Tirzepatide 10 mg
69,90 €
Tirzepatide 10 mg is a synthetic dual-receptor research peptide supplied as a lyophilized powder. It is designed to engage GIP and GLP-1 receptors and is studied in connection with incretin signaling, glucose metabolism, insulin response, appetite regulation, body composition and wider metabolic research.
Key product information:
- Compound: Tirzepatide
- Amount: 10 mg
- Form: Lyophilized powder
- Class: Dual GIP/GLP-1 receptor agonist
- Intended use: Research use only
- Description
- Additional information
Description
Two Incretin Signals, One Defined Peptide Design
Tirzepatide entered peptide research with a simple but ambitious idea:
What if two closely connected metabolic signals could be studied together inside one peptide?
The result was a dual GIP and GLP-1 receptor agonist. This design brings several related research areas together, including appetite, glucose balance, insulin response, food intake, body composition and wider metabolic health.
The Story Behind Tirzepatide
Before receiving its current name, Tirzepatide was known as LY3298176.
Researchers were already familiar with GLP-1 peptides, but GIP offered another important piece of the metabolic picture. The goal was not to mix two separate peptides. It was to create one defined molecule that could communicate with both receptor systems.
Tirzepatide was developed mainly from the natural GIP sequence. Several carefully chosen changes helped the peptide remain available for longer than natural incretin signals.
This is what makes its story interesting. Tirzepatide did not simply add another product to GLP-1 research. It created a new way to explore how two metabolic signals may behave when they are brought together inside one molecule.
Two Signals, Explained Simply
The names may sound complicated, but the basic idea is easy to understand:
- GIP is released after food intake and is studied mainly in connection with insulin response and the way nutrients are handled.
- GLP-1 is linked with appetite, feelings of fullness, digestion, glucose balance and insulin signaling.
Tirzepatide brings both signals into one research model.
Scientists are interested in whether the two pathways support one another, balance one another or create a different overall response when studied together.
Why the Dual-Agonist Idea Attracts Attention
Selective GLP-1 peptides focus mainly on one receptor system. Tirzepatide adds GIP and allows researchers to look at appetite, glucose, insulin, energy balance and body composition as connected parts of the same wider process.
That is why Tirzepatide has attracted attention in research involving weight management, obesity, insulin sensitivity, liver fat and cardiometabolic health.
It is sometimes described online as a “twincretin”, but this is only an informal nickname. The more accurate scientific description is a dual GIP and GLP-1 receptor agonist.
Tirzepatide should therefore not be viewed as simply a “stronger GLP-1 peptide”. Its research value lies in helping scientists explore what changes when two incretin signals are combined inside one molecule.
Future Research Potential
Future research may help explain how combined GIP and GLP-1 signaling is connected with appetite, glucose balance, insulin response, body composition, liver fat and wider metabolic health.
Scientists are also interested in understanding what each signal contributes on its own and what may happen only when both are studied together. These possibilities are still being explored and should not be viewed as guaranteed effects.
Important Notice
For research use only. Not intended for human consumption, veterinary use, diagnostic procedures or therapeutic applications. Before use, carefully review the Safety Data Sheet (SDS/MSDS – KBU). Intended only for experienced researchers and professionals familiar with the safe handling of research-grade materials.
Technical Questions (FAQ)
A dual-receptor agonist is a molecule designed to activate two different receptor systems. Tirzepatide is described as a dual agonist because it is designed to engage both GIP and GLP-1 receptors.
No. This research product is intended only for experienced researchers and professionals working with research-grade materials in controlled settings. It is not intended for human consumption, veterinary use, diagnostic procedures or therapeutic applications.
Lyophilization removes water from the material and helps maintain stability during storage. Exact storage, handling and preparation of the solution should always follow the product documentation and Safety Data Sheet.
The fatty-acid modification helps Tirzepatide connect with albumin, a natural carrier protein found in the body. This allows the peptide to remain available for longer than short-lived natural incretin signals and gives researchers a longer window in which to study it.
Additional information
| CAS | 2023788-19-2 |
|---|
